Obstructive sleep apnea after myocardial infarction. by Fumagalli, Stefano et al.
0167-5273/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.ijcard.2010.04.091
[2] Compton PA, Zankar AA, Adesanya AO, Banerjee S, Brilakis ES. Risk of noncardiac
surgery after coronary drug-eluting stent implantation. Am J Cardiol 2006;98:
1212–3.
[3] Schouten O, Bax JJ, Poldermans D. Management of patients with cardiac stents
undergoing noncardiac surgery. Curr Opin Anaesthesiol 2007;20:274–8.
[4] Godet G, Le Manach Y, Lesache F, Perbet S, Coriat P. Drug-eluting stent thrombosis in
patients undergoing non-cardiac surgery: is it always a problem? Br J Anaes
2008;100:472–7.
[5] Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131:149–50.
Obstructive sleep apnea after myocardial infarction
Stefano Fumagalli a,⁎, Francesca Tarantini a, Chiara Cipriani a, Marta Casalone Rinaldi a, Sanja Jelic b,
Sara Francini a, Yasmine Makhanian a, Margherita Padeletti a, Luigi Padeletti c, Niccolò Marchionni a
a Department of Critical Care Medicine and Surgery, Gerontology and Geriatric Medicine, Intensive Care Unit, University of Florence and AOU Careggi, Florence, Italy
b Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
c Department of Critical Care Medicine and Surgery, Internal Medicine and Cardiology Unit, University of Florence and AOU Careggi, Florence, Italy
a r t i c l e i n f o
Article history:
Received 27 March 2010
Received in revised form 21 April 2010
Accepted 29 April 2010
Available online 1 June 2010
Keywords:
ECG Holter monitoring
Heart rate variability
Myocardial infarction
Obstructive sleep apnea
Ventricular arrhythmias
Obstructive sleep apnea (OSA) is a risk factor for hypertension,
myocardial ischemia and stroke, and is associated with increased
mortality [1,2]. Hypoxia-induced activation of the sympathetic
nervous system, inflammation and oxidative stress contribute to
increase cardiovascular risk in patients with sleep disturbances [2–4].
The present study was aimed at evaluating the prevalence of OSA after
a recent myocardial infarction (MI) and defining its clinical predictors.
All patients with recent MI (median time from symptoms onset:
32 days), admitted to our cardiac rehabilitation center betweenMarch
2007 and December 2008, were enrolled in the study. All subjects
were in stable clinical conditions.
At baseline, patients underwent echocardiogram, ECG Holter,
ergometric stress test, and blood tests. Ventricular arrhythmia risk
profile was quantified on ECG Holter analysis, using the Lown and
Wolf classification: frequent (N30/h) and complex (presence of
couplets and tachycardia) arrhythmias [5]. Frequent supraventricular
arrhythmia was defined as a number of ectopic beats N30/h. The peak
CPK-MB and Troponin I values detected during acute MI were
registered.
The presence of OSA was assessed by ECG Holter recording using
a validated software (Lifescreen Apnea; SPACELABS Healthcare —
Issaquah, Washington, USA and Hertford, UK) integrated in the
Impresario Holter Analysis System (Symphony model; SPACELABS
Healthcare). Briefly, the continuous change from airways obstruction
to normal air flow determines a shift from sympathetic to para-
sympathetic dominance, with related changes in heart rate. The
software analyzes modifications in heart rate variability (HRV) and in
QRS amplitude, returning the mean apnea-hypopnea index (AHI)
[6,7]. Diagnostic sensitivity of this technique, compared to polysom-
nography, is 90% [6,7]. ECG Holter recorders had a sampling rate of
2048 Hz (EVO recorder; SPACELABS Healthcare). Patients were
stratified on AHI values into three groups: normal (AHI≤5), mild
(AHI 5–15) and moderate-severe apnea (AHIN15) [1,2]. Two para-
meters of HRV in time domain analysis were evaluated, SDNN (the
standard deviation of RR intervals of the ECG Holter recording) and
RMSSD (the square root of the mean squared differences of successive
RR intervals), corresponding to sympathetic and parasympathetic
activity— the former, and to parasympathetic activity only— the latter
[8].
Exclusion criteria for the study were: dominant non-sinus rhythm;
presence of an implanted pacemaker; frequent artifacts in the ECG
Holter recording; diabetes mellitus type 1 and other conditions
associated with a severe autonomic dysfunction.
Each patient gave written informed consent to the study; the
protocol conforms to the ethical guidelines of the 1975 Declaration of
Helsinki.
Continuous and categorical variables were expressed as mean±
standard deviation (SD) and percentages, respectively. For continuous
variables, Student's t test or analysis of variance were employed to
compare two or more groups of subjects. When the variables were not
normally distributed, non parametric tests were employed. The
association between two continuous variables was assessed with
linear regression analysis. Differences in categorical variables dis-
tribution were evaluated with χ2 test.
To identify the clinical predictors of OSA, those factors correlated to
this condition in univariate analysis, were entered into a multivariate
linear regression model.
We enrolled 191 patients (Table 1), 73% after a ST-elevation MI
(STEMI). Primary percutaneous coronary intervention was performed
in 84% of cases. Mean peak values of CPK-MB and troponin I were
113 UI/L (25th–75th percentile: 38–145 UI/L) and 106 ng/mL (25th–
75th percentile: 16–141 ng/mL), respectively (Table 2).
The maximum workload attained at the baseline ergometric
stress test was 118±40 Watt. The test was suggestive of myocardial
ischemia only in 18 patients (9.4%).
ECG Holter recordings had a mean length of 22:09±1:27 h. Mean
heart rate was 66±9 b/min. SDNN and RMSSD were within lower
normal limits (Table 2). Second or third degree atrioventricular blocks
were absent, cardiac pauses longer than 2 s were present only in 7
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patients (3.7%). ST segment depression was observed in 6 patients
(3.1%).
Mean sleep time was 7:56±1:13 h; 143 subjects (74.9%) had AHI
scores N5, with a mean value of 17.7±10.8 (mild: N=67, 35.3%;
moderate-severe apnea: N=76, 40.1%).
Body weight correlated directly with AHI (Table 3), with the
highest value observed in moderate-severe apnea patients (normal:
75±13 kg, mild: 74±11 kg, moderate-severe apnea: 80±12 kg;
p=0.029).
Uncontrolled hypertension (i.e. blood pressure N130/80 mmHg at
the time of enrollment), was positively associated with AHI. AHI
linearly increased with uric acid and CPK-MB plasma concentrations,
and RBC count (Table 3). While patients with STEMI displayed higher
values of AHI (Table 3), no relation was found with residual LVEF
(p=0.536) (Table 3). Complex ventricular arrhythmias directly cor-
related with AHI (Table 3), with the highest prevalence of frequent
ventricular arrhythmias in themoderate-severe group (normal: 12.5%,
mild: 18.8%, moderate-severe apnea: 68.8%; p=0.033).
The multivariate linear regression analysis confirmed the direct
correlation of AHI with body weight, RBC count, use of K+ sparing
agents, presence of uncontrolled hypertension and complex ventri-
cular arrhythmias (Table 4).
This study suggests that OSA is highly prevalent in patients with a
recent MI. The study was conducted 4 weeks after MI to exclude
possible confounders, such as acute inflammation and overt left ven-
tricular failure. CPK-MB peak plasma concentration and STEMI, two
indicators of MI extension, correlated with the severity of OSA. Fur-
thermore, K+ sparing agents, more frequently prescribed in patients
with moderate-severe left ventricular dysfunction (pb0.001), were
associated with greater AHI. A strong relationwas found between OSA
and RBC count, corroborating previous reports of a predictive value of
hemoglobin and hematocrit for the presence of sleep disturbances [9].
The correlation between AHI and plasma levels of uric acid, possibly
related to enhanced ATP transformation, may suggest tissue distress
[10].
Table 1
Clinical characteristics of patients.
Range
Age (years) 62±13 28–94
Men (%) 81.7
Weight (kg) 77±13 47–115
BMI (kg/m2) 26.6±3.5 16.3–40.2
Smokers
Current (%) 21.6
Past (%) 51.1
Comorbidities
COPD (%) 7.9
Diabetes (%) 15.3
Dyslipidemia (%) 45.0
Hypertension (%) 56.3
Previous MI (%) 8.7
Stroke/TIA (%) 3.6
Valvular heart diseases
Aortic insufficiency (%) 3.2
Aortic stenosis (%) 10.2
Mitral insufficiency (%) 9.7
Blood tests
Creatinine (mg/dL) 0.95±0.24 0.50–2.00
ESR (mm/h) 27.2±20.1 2.0–111.0
Hemoglobin (g/dL) 13.5±1.4 10.0–16.4
RBC count (106/mm3) 4.6±0.5 3.4–7.0
Uric acid (mg/dL) 5.9±1.3 2.0–9.7
BMI: body mass index; CABG: coronary artery bypass graft; COPD: chronic obstructive
pulmonary disease; ESR: erythrocyte sedimentation rate.
Table 2
Cardiological characteristics of patients and drug therapy.
Range
Type of myocardial infarction
Anterior STEMI (%) 36.6
Inferior STEMI (%) 36.6
NSTEMI (%) 26.8
Primary PCI site
Left main (%) 0.5
Left anterior descending (%) 41.7
Circumflex (%) 12.3
Right CA (%) 29.4
No PCI (%) 16.0
LVEF (%) 52±11 20–74
Preserved (%) 62.4
Mild reduction (%) 19.4
Moderate/severe reduction (%) 18.2
ECG Holter monitoring
Frequent SV arrhythmias (%) 4.7
Frequent V arrhythmias (%) 8.4
Complex V arrhythmias (%) 36.6
SDNN (ms) 116±34 37–222
RMSSD (ms) 33±20 10–128
Drug therapy
ASA (%) 96.9
Clopidogrel (%) 95.3
ACE inhibitors/ATII antagonists (%) 94.8
β-blocking agents (%) 89.5
Statins (%) 93.2
K+ sparing agents (%) 14.7
Diuretics (%) 22.5
AT: angiotensin; CA: coronary artery; LVEF: left ventricular ejection fraction —
categorized as normal (N50%), mildly (41–49%), moderately (26–40%), and severely
(b25%) depressed; MI: myocardial infarction; PCI: percutaneous coronary intervention;
RMSSD: root mean square of the squared difference between consecutive RR intervals;
SDNN: standard deviation of all RR intervals of the ECG Holter recording; STEMI/
NSTEMI: ST-/non-ST-elevation MI; SV/V: supraventricular/ventricular.
Table 3
Univariate analysis of apnea-hypopnea index by clinical variables.
Condition p
− +
Men 8.0±6.9 15.2±11.8 b0.001
Present smokers 13.7±11.4 14.8±11.8 0.584
COPD 14.0±11.6 13.6±10.0 0.893
Diabetes 13.7±11.6 15.3±11.7 0.907
History of hypertension 13.4±10.8 14.4±12.0 0.551
Uncontrolled hypertension 12.5±10.2 16.1±13.1 0.039
Stroke/TIA 14.1±11.6 9.1±8.4 0.293
Aortic insufficiency 13.6±11.6 22.8±8.3 0.055
Aortic stenosis 14.1±11.5 13.6±12.1 0.868
Mitral insufficiency 14.2±11.6 13.3±11.4 0.515
Frequent SV arrhythmias (%) 14.4±11.5 5.5±6.1 0.023
Complex V arrhythmias (%) 12.5±10.2 16.2±13.0 0.029
STEMI 11.6±10.6 15.0±11.8 0.049
ACE inhibitors/AT II antagonists 19.9±11.9 13.6±11.4 0.092
β-blocking agents 15.1±15.8 13.8±10.9 0.623
Statins 12.5±15.1 14.1±11.2 0.645
K+ sparing agents 13.3±11.0 18.1±13.6 0.048
Diuretics 14.5±12.0 12.0±9.4 0.206
β±se R p
Age (Δ·year) / 0.035 0.633
Weight (Δ·kg) 0.23±0.07 0.243 0.001
BMI (Δ·kg/m2) / 0.138 0.059
CPK MB (Δ·UI/L) 0.04±0.01 0.364 0.001
Creatinine (Δ·mg/dL) / 0.108 0.148
ESR (Δ·mm/h) / 0.077 0.299
Hemoglobin (Δ·g/dL) / 0.138 0.062
RBC count (Δ·106/mm3) 3.8±1.5 0.179 0.015
Uricemia (Δ·mg/dL) 1.5±0.7 0.159 0.032
HR (Δ·b/min) / 0.032 0.661
SDNN (Δ·ms) / 0.117 0.111
RMSSD (Δ·ms) / 0.133 0.071
`Uncontrolled hypertension: blood pressure N130/80 mmHg at baseline evaluation;
SV/V: supraventricular/ventricular; Δ: AHI changes per unitary change of the
independent variable. Variables represented in less than 5% of the study
population were excluded from the analysis.
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Table 4
Clinical predictors of apnea–hypopnea index by multivariate linear regression analysis
(R=0.435, pb0.001).
β±se 95%CI p
Body weight (Δ·Kg) 0.2±0.1 0.1–0.3 0.001
RBC count (Δ·106/mm3) 3.0±1.5 0.1–5.8 0.043
Complex V arrhythmias (yes vs. no) 3.5±1.6 0.3–6.8 0.030
Frequent SV arrhythmias (yes vs. no) −9.5±3.7 −(16.7–2.3) 0.010
Uncontrolled hypertension (yes vs. no) 4.2±1.6 1.0–7.4 0.011
K+ sparing agents (yes vs. no) 5.2±2.3 0.7–9.8 0.024
Constant −20.1±8.0 −(35.9–4.4) 0.013
Δ: AHI changes per unitary change of the independent variable; RBC: red blood cell; SV/
V: supraventricular/ventricular.
The association between AHI and complex ventricular arrhythmias
is an important novel finding. In the Sleep Heart Health Study, the
presence of a sleep disturbance, increased about three times the risk to
develop a not sustained ventricular tachycardia, and at least two times
the risk to experience complex ventricular arrhythmias [11]. The
correlation between OSA and ventricular arrhythmias might be
explained by several factors, including increased left ventricular
afterload with consequent reduction in preload, increased sympa-
thetic outflow, and the possible presence of diastolic dysfunction [12].
Few limitations of the study need to be acknowledged. Only 2
patients reported the use of a CPAP previous to the occurrence of MI,
but we cannot rule out the possibility that subclinical sleep dis-
turbances might have been present before the acute event in a portion
of our population. The technique we used to detect OSA, even if
validated, employs only the electrocardiographic dimension of the
polysomnography study. It is known that a recent MI may reduce HRV
influencing the ability of ECG analysis to detect sleep apnea. However,
HRV recorded in our study population was still within normal limits
[8]; moreover, a reduction of HRV should determine an under-
estimation of the prevalence of sleep disturbances. Furthermore, a
recent Scientific Statement on sleep apnea and cardiovascular disease,
recommended to adopt new non-invasive tools of screening, less
expensive and more widely applicable than standard polysomnogra-
phy [1].
In conclusion, previously unrecognized OSA is highly prevalent
among patients with recent MI and associates with increased body
weight, uncontrolled hypertension and complex ventricular arrhyth-
mias. Clinicians should seek and treat sleep disturbances when
occurring in patients with recent MI.
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